170 related articles for article (PubMed ID: 21356299)
1. New perspectives of 19F MAS NMR in the characterization of amorphous forms of atorvastatin in dosage formulations.
Brus J; Urbanova M; Sedenkova I; Brusova H
Int J Pharm; 2011 May; 409(1-2):62-74. PubMed ID: 21356299
[TBL] [Abstract][Full Text] [Related]
2. Characterization of solid polymer dispersions of active pharmaceutical ingredients by 19F MAS NMR and factor analysis.
Urbanova M; Brus J; Sedenkova I; Policianova O; Kobera L
Spectrochim Acta A Mol Biomol Spectrosc; 2013 Jan; 100():59-66. PubMed ID: 22421443
[TBL] [Abstract][Full Text] [Related]
3. Solid-state NMR studies of form I of atorvastatin calcium.
Wang WD; Gao X; Strohmeier M; Wang W; Bai S; Dybowski C
J Phys Chem B; 2012 Mar; 116(11):3641-9. PubMed ID: 22360640
[TBL] [Abstract][Full Text] [Related]
4. Preparation, characterization and in vivo evaluation of amorphous atorvastatin calcium nanoparticles using supercritical antisolvent (SAS) process.
Kim MS; Jin SJ; Kim JS; Park HJ; Song HS; Neubert RH; Hwang SJ
Eur J Pharm Biopharm; 2008 Jun; 69(2):454-65. PubMed ID: 18359211
[TBL] [Abstract][Full Text] [Related]
5. Quantification of atorvastatin calcium in tablets by FT-Raman spectroscopy.
Mazurek S; Szostak R
J Pharm Biomed Anal; 2009 Jan; 49(1):168-72. PubMed ID: 19062220
[TBL] [Abstract][Full Text] [Related]
6. Quantification of compaction-induced crystallinity reduction of a pharmaceutical solid using 19F solid-state NMR and powder X-ray diffraction.
Liu J; Nagapudi K; Kiang YH; Martinez E; Jona J
Drug Dev Ind Pharm; 2009 Aug; 35(8):969-75. PubMed ID: 19360510
[TBL] [Abstract][Full Text] [Related]
7. 13C and 15N CP/MAS, 1H-15N SCT CP/MAS and FTIR spectroscopy as tools for qualitative detection of the presence of zwitterionic and non-ionic forms of ansa-macrolide 3-formylrifamycin SV and its derivatives in solid state.
Przybylski P; Pyta K; Klich K; Schilf W; Kamieński B
Magn Reson Chem; 2014; 52(1-2):10-21. PubMed ID: 24347399
[TBL] [Abstract][Full Text] [Related]
8. Factor analysis of 27Al MAS NMR spectra for identifying nanocrystalline phases in amorphous geopolymers.
Urbanova M; Kobera L; Brus J
Magn Reson Chem; 2013 Nov; 51(11):734-42. PubMed ID: 24027195
[TBL] [Abstract][Full Text] [Related]
9. Solid state NMR and DSC methods for quantifying the amorphous content in solid dosage forms: an application to ball-milling of trehalose.
Lefort R; De Gusseme A; Willart JF; Danède F; Descamps M
Int J Pharm; 2004 Aug; 280(1-2):209-19. PubMed ID: 15265560
[TBL] [Abstract][Full Text] [Related]
10. Crystal forms of atorvastatin.
An SG; Sohn YT
Arch Pharm Res; 2009 Jun; 32(6):933-6. PubMed ID: 19557372
[TBL] [Abstract][Full Text] [Related]
11. Effect of counterions on the properties of amorphous atorvastatin salts.
Sonje VM; Kumar L; Puri V; Kohli G; Kaushal AM; Bansal AK
Eur J Pharm Sci; 2011 Nov; 44(4):462-70. PubMed ID: 21907794
[TBL] [Abstract][Full Text] [Related]
12. Quantitation of a polymorphic mixture of an active pharmaceutical ingredient with solid state (13)C CPMAS NMR spectroscopy.
Virtanen T; Maunu SL
Int J Pharm; 2010 Jul; 394(1-2):18-25. PubMed ID: 20416365
[TBL] [Abstract][Full Text] [Related]
13. Quantification of gabapentin polymorphs in gabapentin/excipient mixtures using solid state
Tinmanee R; Larsen SC; Morris KR; Kirsch LE
J Pharm Biomed Anal; 2017 Nov; 146():29-36. PubMed ID: 28843174
[TBL] [Abstract][Full Text] [Related]
14. X-[1H, 19F] triple resonance with a X-[1H] CP MAS probe and characterisation of a 29Si-19F spin pair.
Bechmann M; Hain K; Marichal C; Sebald A
Solid State Nucl Magn Reson; 2003; 23(1-2):50-61. PubMed ID: 12633831
[TBL] [Abstract][Full Text] [Related]
15. Solid state characterization of commercial crystalline and amorphous atorvastatin calcium samples.
Shete G; Puri V; Kumar L; Bansal AK
AAPS PharmSciTech; 2010 Jun; 11(2):598-609. PubMed ID: 20352531
[TBL] [Abstract][Full Text] [Related]
16. Characterizing crystal disorder of trospium chloride: a comprehensive,(13) C CP/MAS NMR, DSC, FTIR, and XRPD study.
Urbanova M; Sturcova A; Brus J; Benes H; Skorepova E; Kratochvil B; Cejka J; Sedenkova I; Kobera L; Policianova O; Sturc A
J Pharm Sci; 2013 Apr; 102(4):1235-48. PubMed ID: 23359249
[TBL] [Abstract][Full Text] [Related]
17. Isolation and structure determination of oxidative degradation products of atorvastatin.
Kracun M; Kocijan A; Bastarda A; Grahek R; Plavec J; Kocjan D
J Pharm Biomed Anal; 2009 Dec; 50(5):729-36. PubMed ID: 19615842
[TBL] [Abstract][Full Text] [Related]
18. Solid-state NMR in the analysis of drugs and naturally occurring materials.
Paradowska K; Wawer I
J Pharm Biomed Anal; 2014 May; 93():27-42. PubMed ID: 24173236
[TBL] [Abstract][Full Text] [Related]
19. Alternate strategies to obtain mass balance without the use of radiolabeled compounds: application of quantitative fluorine (19F) nuclear magnetic resonance (NMR) spectroscopy in metabolism studies.
Mutlib A; Espina R; Atherton J; Wang J; Talaat R; Scatina J; Chandrasekaran A
Chem Res Toxicol; 2012 Mar; 25(3):572-83. PubMed ID: 22292524
[TBL] [Abstract][Full Text] [Related]
20. Solid state 19F NMR parameters of fluorine-labeled amino acids. Part I: aromatic substituents.
Dürr UH; Grage SL; Witter R; Ulrich AS
J Magn Reson; 2008 Mar; 191(1):7-15. PubMed ID: 18155936
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
